- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00412763
Efficacy of Silymarin for Acute Hepatitis
Efficacy of Silymarin for Treatment of Acute Hepatitis In Egypt: A Randomized, Double-Blinded, Controlled Trial
Study Overview
Detailed Description
The study is designed as a double-blinded placebo controlled trial. We compare a 4 week course of therapy with silymarin tablets and a low-dose vitamin preparation (placebo) and then follow-up for a total of 8 weeks to assess treatment response. Outcomes of our randomized controlled trial are improvement in symptoms and signs, normalization of liver functions, time to resuming normal activities, and and sense of well-being. This protocol follows the standard therapeutic care for acute hepatitis except that the patients will receive either a herbal supplement (silymarin), which many patients are taking anyway, or a vitamin placebo.
Freshly collected serum will be tested for anti-HAV IgM, anti-HBc Igm, anti-HBs, HBs Ag, anti-HCV antibody, HCV-RNA, anti-HDV IgM, anti-HEV IgM, CMV and EBV and for alanine aminotransferase (ALT), AST, direct and total bilirubin.
Study Type
Enrollment
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients admitted to the fever hospital and presenting with symptoms and signs that may be consistent with a diagnosis of acute hepatitis.
- Recent (<1 month) history of illness.
- Elevation of ALT > 2.5 normal.
- At least 13 years old.
Exclusion Criteria:
- History suggestive of severe drug-induced acute hepatitis.
- Children 12 years and younger.
- Pregnant or breastfeeding women
- Suspected hypersensitivity to Silymarin or vitamin preparations.
- Evidence of advanced liver disease e.g. history or presence of ascitis, bleeding esophageal varices, and hepatic encephalopathy.
- Patients who are critically ill, with multisystem failure or cancer.
- Substance abuse such as IV drugs.
- Any other conditions, which in the opinion of the investigator would make the patient unsuitable for enrollment or could interfere with the patient's participation in and completion of the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Primary outcomes were symptoms and signs of acute hepatitis and results of liver function tests on days 3, 5 and 7 in the hospital and in the outpatient clinic at weeks 2, 4, and 8.
|
Secondary Outcome Measures
Outcome Measure |
---|
Side-effects and adverse events were ascertained by self-report on days 3, 5 and 7 in the hospital and in the outpatient clinic at weeks 2, 4, and 8. .
|
Collaborators and Investigators
Investigators
- Principal Investigator: George T Strickland, MD, PhD, University of Maryland, Baltimore
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Liver Diseases
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Antioxidants
- Silymarin
Other Study ID Numbers
- H-21829
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis
-
University of Maryland, BaltimoreAlexandria University; MADAUS GmbH; The Egyptian Company for Blood Transfusion... and other collaboratorsTerminatedAcute Hepatitis C | Acute Hepatitis B | Acute Hepatitis A | Acute Hepatitis E | Acute EBV Hepatitis | Acute CMV HepatitisEgypt
-
Gilead SciencesCompletedChronic Hepatitis DeltaFrance, Moldova, Republic of, Romania, Russian Federation
-
Ziauddin HospitalUnknown
-
National Taiwan University HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanUnknownChronic Hepatitis B | Chronic Hepatitis DTaiwan
-
Hepatera Ltd.CompletedChronic Hepatitis D Infection
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Beijing Kawin Technology Share-Holding Co., Ltd.CompletedChronic Hepatitis cChina
Clinical Trials on Silymarin (Silybum marianum)
-
Sun Yat-sen UniversityActive, not recruitingFatty Liver DiseaseChina
-
Vanderbilt UniversityWithdrawn
-
Madaus IncUniversity of Pennsylvania; Beth Israel Deaconess Medical Center; University... and other collaboratorsCompletedNon-alcoholic SteatohepatitisUnited States
-
Herbert Irving Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedLeukemia | Drug/Agent Toxicity by Tissue/OrganUnited States, Canada
-
Isfahan University of Medical SciencesMadaus IncUnknownIron Overload | Beta-thalassemia MajorIran, Islamic Republic of
-
University of Sao Paulo General HospitalUniversity of Sao PauloCompletedHealthy | Inflammatory Bowel Diseases | Insulin Resistance | Overweight and ObesityBrazil
-
Shiraz University of Medical SciencesCompletedImmune AbnormalitiesIran, Islamic Republic of
-
Tanta UniversityNot yet recruiting
-
Ramathibodi HospitalCompleted
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)CompletedHepatitis C, Chronic